

January 2013

## Cerium oxide nanoparticles: influence of the high-Z component revealed on radioresistant 9L cell survival under X-ray irradiation

Adam Briggs

*University of Wollongong, arb938@uowmail.edu.au*

stephanie corde

*University of Wollongong, scorde@uow.edu.au*

Sianne Oktaria

*University of Wollongong, so819@uowmail.edu.au*

Ryan Brown

*University of Wollongong, rsb084@uowmail.edu.au*

Anatoly B. Rosenfeld

*University of Wollongong, anatoly@uow.edu.au*

*See next page for additional authors*

Follow this and additional works at: <https://ro.uow.edu.au/ihmri>



Part of the [Medicine and Health Sciences Commons](#)

---

### Recommended Citation

Briggs, Adam; corde, stephanie; Oktaria, Sianne; Brown, Ryan; Rosenfeld, Anatoly B.; Lerch, Michael; Konstantinov, Konstantin; and Tehei, Moeava, "Cerium oxide nanoparticles: influence of the high-Z component revealed on radioresistant 9L cell survival under X-ray irradiation" (2013). *Illawarra Health and Medical Research Institute*. 358.

<https://ro.uow.edu.au/ihmri/358>

---

## Cerium oxide nanoparticles: influence of the high-Z component revealed on radioresistant 9L cell survival under X-ray irradiation

### Abstract

This article pioneers a study into the influence of the high-Z component of nanoparticles on the efficacy of radioprotection some nanoparticles offer to exposed cells irradiated with X-rays. We reveal a significant decrease in the radioprotection efficacy for cells exposed to CeO<sub>2</sub> nanoparticles and irradiated with 10 MV and 150 kVp X-rays. In addition, analysis of the 150 kVp survival curve data indicates a change in radiation quality, becoming more lethal for irradiated cells exposed to CeO<sub>2</sub> nanoparticles. We attribute the change in efficacy to an increase in high linear energy transfer Auger electron production at 150 kVp which counterbalances the CeO<sub>2</sub> nanoparticle radioprotection capability and locally changes the radiation quality. This study highlights an interesting phenomenon that must be considered if radiation protection drugs for use in radiotherapy are developed based on CeO<sub>2</sub> nanoparticles.

### Keywords

radioresistant, 9l, cell, survival, under, x, ray, irradiation, nanoparticles, influence, high, z, component, cerium, revealed, oxide

### Disciplines

Medicine and Health Sciences

### Publication Details

Briggs, A., corde, s., Oktaria, S., Brown, R., Rozenfeld, A., Lerch, M., Konstantinov, K. & Tehei, M. (2013). Cerium oxide nanoparticles: influence of the high-Z component revealed on radioresistant 9L cell survival under X-ray irradiation. *Nanomedicine*, 9 (7), 1098-1105.

### Authors

Adam Briggs, stephanie corde, Sianne Oktaria, Ryan Brown, Anatoly B. Rosenfeld, Michael Lerch, Konstantin Konstantinov, and Moeava Tehei

Title: Cerium oxide nanoparticles: Influence of the high-Z component revealed on radioresistant 9L cell survival under X-ray irradiation

Article Type: Original Article

Keywords: Cerium oxide nanoparticles; High-Z; Radioprotectors; Photoelectric effect; Radioresistant.

Corresponding Author: Dr. Moeava Tehei, Ph D.


Corresponding Author's Institution: UOW

First Author: Adam Briggs

Order of Authors: Adam Briggs; Stéphanie Corde; Sianne Oktaria; Ryan Brown; Anatoly Rosenfeld; Michael Lerch; Konstantin Konstantinov; Moeava Tehei, Ph D.; Moeava Tehei

Abstract: This article pioneers a study into the influence of the high-Z component of nanoparticles on the efficacy of radioprotection some nanoparticles offer to exposed cells irradiated with X-rays. We reveal a significant decrease in the radioprotection efficacy for cells exposed to CeO<sub>2</sub> nanoparticles and irradiated with 10 MV and 150 kVp X-rays. In addition, analysis of the 150 kVp survival curve data indicates a change in radiation quality, becoming more lethal for irradiated cells exposed to CeO<sub>2</sub> nanoparticles. We attribute the change in efficacy to an increase in high linear energy transfer Auger electron production at 150 kVp which counterbalances the CeO<sub>2</sub> nanoparticle radioprotection capability and locally changes the radiation quality. This study highlights an interesting phenomenon that must be considered if radiation protection drugs for use in radiotherapy are developed based on CeO<sub>2</sub> nanoparticles.

A counterbalance exists between radioprotection and enhancement for CeO<sub>2</sub> NPs. The influence of this high-Z property is revealed on radioresistant 9L cells, where greater radioprotection was achieved using 10 MV photons in comparison to that achieved when using 150 kVp X-rays. At lower energies, high-LET Auger electron cascades create clustered, indirect and dominant direct damages and free radicals that are scavenged by CeO<sub>2</sub> or recombine resulting in formation of H<sub>2</sub>O. Conversely, at higher energies, low-LET secondary electrons create dominantly free radicals that both: are scavenged by CeO<sub>2</sub> NPs and can indirectly damage DNA. This unique mechanism should be considered throughout all nanoparticle based radiotherapy where high-Z nanoparticles such as CeO<sub>2</sub> are used.



# Cerium oxide nanoparticles: Influence of the high-Z component revealed on radioresistant 9L cell survival under X-ray irradiation

Adam Briggs, BMedRadPhysAdv<sup>a,b</sup>, Stéphanie Corde, PhD<sup>a,c</sup>,  
Sianne Oktaria, MMedRadPhys<sup>a,b,d</sup>, Ryan Brown, BMedRadPhysAdv<sup>a,b</sup>,  
Anatoly Rosenfeld, PhD<sup>a,b</sup>, Michael Lerch, PhD<sup>a,b</sup>, Konstantin Konstantinov, PhD<sup>f,b</sup>,  
Moeava Tehei, PhD<sup>d,b,e,\*</sup>

<sup>a</sup>Centre for Medical and Radiation Physics, University of Wollongong, NSW, Australia

<sup>b</sup>Illawarra Health and Medical Research Institute, University of Wollongong, NSW, Australia

<sup>c</sup>Radiation Oncology Department, Prince of Wales Hospital, Randwick, NSW, Australia

<sup>d</sup>Centre for Medical Bioscience, University of Wollongong, NSW, Australia

<sup>e</sup>School of Chemistry, University of Wollongong, Wollongong, NSW, Australia

<sup>f</sup>Institute for Superconducting and Electronic Materials, University of Wollongong, NSW, Australia

---

---

**Short title:** Effect of high-Z components revealed on CeO<sub>2</sub> NPs (48 characters inc. spaces)

**Sources of research support:** AINSE research fellowship, small UoW Near Miss grant and a small URC grant

**Abstract word count:** 135

**Manuscript word count:** 4920

**Number of figures:** 4

**Number of tables:** 1

**Number of references:** 38

---

\*Corresponding author. Centre for Medical Bioscience, University of Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia.

*Email address:* moeava@uow.edu.au (Moeava Tehei, PhD)

---

## Abstract

This article pioneers a study into the influence of the high-Z component of nanoparticles on the efficacy of radioprotection some nanoparticles offer to exposed cells irradiated with X-rays. We reveal a significant decrease in the radioprotection efficacy for cells exposed to CeO<sub>2</sub> nanoparticles and irradiated with 10 MV and 150 kVp X-rays. In addition, analysis of the 150 kVp survival curve data indicates a change in radiation quality, becoming more lethal for irradiated cells exposed to CeO<sub>2</sub> nanoparticles. We attribute the change in efficacy to an increase in high linear energy transfer Auger electron production at 150 kVp which counterbalances the CeO<sub>2</sub> nanoparticle radioprotection capability and locally changes the radiation quality. This study highlights an interesting phenomenon that must be considered if radiation protection drugs for use in radiotherapy are developed based on CeO<sub>2</sub> nanoparticles.

*Keywords:* Cerium oxide nanoparticles, High-Z, Radioprotectors, Photoelectric effect, Radioresistant

---

1 The application of nanotechnology to medicine provides an innovative approach that can  
2 enhance the effectiveness of radiotherapy<sup>1</sup>. Targeted and non-targeted tissues and cells are,  
3 in general, damaged along an indirect pathway during radiation treatment as a result of the  
4 production of free radicals<sup>2</sup>. Free radical production can result in chemical reactions that damage  
5 DNA molecules and initiates apoptosis and mitotic death<sup>3,4</sup>. The protective mechanisms of a  
6 cell in response to ionizing radiation exposure are insufficient and have prompted the research and  
7 development of novel nanoparticles (NPs) with the ability to enhance or assist cell protective  
8 mechanisms. If such NPs act preferentially and protect normal tissues that surround target  
9 tissues it would allow dose escalation to the target for better tumour control and hence improved  
10 patient outcomes.

11 One novel nanoparticle currently under investigation for its ability to provide protection against

12 radiation induced damage is cerium oxide ( $\text{CeO}_2$ )<sup>5</sup>. Previous studies investigated the free-radical  
13 scavenging effectiveness of  $\text{CeO}_2$  NPs to provide radioprotection *in vitro* for a variety of normal  
14 cell lines, and *in vivo* with athymic nude mice<sup>6,7</sup>.  $\text{CeO}_2$  NPs inherit an autoregenerative cycle  
15 ( $\text{Ce}^{3+} \rightarrow \text{Ce}^{4+} \rightarrow \text{Ce}^{3+}$ ) that enables continued antioxidant activity, providing long-term scavenging  
16 of reactive oxygen species (ROS)<sup>8</sup>.  $\text{CeO}_2$  NPs now offer a prospective alternative to the only  
17 clinically used radioprotector — amifostine<sup>9</sup>. Amifostine has the limitation of considerable side  
18 effects, a short half-life in serum and high cost caused by frequent dosing requirements<sup>3</sup>.  
19 Many avenues need to be explored prior to the clinical acceptance of  $\text{CeO}_2$  NPs and its application  
20 as a radioprotector. Current investigations using  $\text{CeO}_2$  NPs explore characteristics such as:  
21 its bioavailability/toxicity<sup>10-12</sup>, the ability to provide radiation protection by scavenging free  
22 radicals and the selective nature of its protection to normal and cancerous cells<sup>7</sup>. However, steps  
23 towards the clinical acceptance of  $\text{CeO}_2$  NPs requires an understanding of its effectiveness across  
24 a range of beam energies. To the best of our knowledge, the influence of the above effects have  
25 never been reported in the literature.

26 X-rays used throughout clinical treatments produce free radicals through interactions with mat-  
27 ter<sup>2</sup>. Interactions of interest include — photoelectric and Compton effects, coherent scattering  
28 along with pair production at higher energies. The most influential factors dictating the cross-  
29 section for these interactions is the radiation energy (E) and atomic number (Z). The mass  
30 attenuation coefficient due to the photoelectric effect is approximately proportional to  $(Z/E)^3$ ,  
31 where Z is the atomic number of the absorbing medium and E is the photon energy<sup>13</sup>. The use of  
32 high-Z nanoparticles (i.e. gold NPs,  $Z_{Au} = 79$ ) in dose enhancement provides an example of how  
33 we can exploit the dependence of the photoelectric effect<sup>13-15</sup>. The majority of Auger electrons  
34 are produced as a consequence of the photoelectric effect supporting the notion that their  
35 greatest abundance is achieved when the cross-section for the photoelectric effect is maximised.  
36 Compton interactions occur with outer shell electrons and subsequently, have no significant Z  
37 dependence<sup>16</sup>. A threshold photon energy of 1.022 MeV exists for pair production, with a cross  
38 section that increases rapidly with energy above the threshold<sup>13</sup>. Furthermore, pair production  
39 cross-section has a quadratic proportionality with Z. The linear energy transfer (LET) is a  
40 measure of the energy locally imparted to a medium by a secondary charged particle of energy  
41 (E) along its path<sup>2,16</sup>. The variation of the LET with decreasing electron energy is an important

42 consideration in our study as increases in LET correspond to increases in the relative biological  
43 effectiveness (RBE) of the radiation field<sup>17</sup>. Auger electrons have a LET that lies in the range of  
44 10 - 25 keV/ $\mu\text{m}$ <sup>18</sup> while the positron-electron pair produced during the pair production process  
45 with kinetic energy of a few MeV have a LET of 0.2 keV/ $\mu\text{m}$ <sup>17</sup>. Ultimately, Auger electrons  
46 deposit their energy along their tracks in a very short range, indicating an increase in the  
47 biological effectiveness of radiation exposure at lower energies<sup>13</sup>. CeO<sub>2</sub> is a known radioprotector  
48 however, the high-Z ( $Z_{Ce} = 58$ ) component of this material is the major contributor towards  
49 potential increases in the RBE.

50 In this article, we postulate that CeO<sub>2</sub> NPs efficacy to function as a radioprotector is dependent  
51 on the energy of X-rays used during treatment and we investigated this energy-dependence using  
52 150 kVp X-ray and 10 MV photon beams. Furthermore, to prove the existence of any high-Z  
53 enhancement abilities that CeO<sub>2</sub> may possess, we select the radioresistant 9L cell line.

54 Cell survival curves are an effective analytical method that we utilise to measure the effectiveness  
55 of CeO<sub>2</sub> NPs to provide radioprotection. Radiobiological properties such as radiosensitivity and  
56 repair accumulation can be extracted using this analysis, where the influence on these parameters  
57 by the CeO<sub>2</sub> NP are determined for the first time.

58 Our study reveals an energy-dependent efficacy due to the influence of the high-Z component  
59 of CeO<sub>2</sub> NPs ( $Z_{eff} = 54$ ). At 10 MV, indirect damage effects dominate and mainly results  
60 from the interaction of molecules contained in cells and the free radicals produced during the  
61 radiolysis of water. The radioprotection provided by CeO<sub>2</sub> NPs is achieved using free-radical  
62 scavenging effects, facilitating increased repair while lowering the cells radiosensitivity. At lower  
63 X-ray beam energies, the probability of direct damage effects become an increasingly important  
64 consideration and are no longer negligible<sup>17</sup>. Low energy secondary electrons have an increased  
65 probability to produce clusters of free radicals that can provoke the rupture of covalent bonds  
66 and scissions in the molecules contained within cells<sup>17</sup>. The additional presence of free radicals  
67 cannot be fully managed by the scavenging abilities of CeO<sub>2</sub>, adding further weight to increased  
68 damaging effects at lower energies. The work described in this article reveals that the free-radical  
69 scavenging effect is counterbalanced by the high-Z atoms present in the elemental composition  
70 of CeO<sub>2</sub>. These high-Z atoms are responsible for an increased production of lethally damaging,  
71 low energy secondary electrons.

## 72 **Methods**

### 73 *Cell line*

74 The rat brain gliosarcoma cell line (9L) was obtained from the European Collection of Cell  
75 Cultures (ECACC). Derived from a N-nitrosomethylurea-induced tumour, this adherent radiore-  
76 sistant cell line inherits glial morphology and has undergone routine mycoplasma contamination  
77 testing.

### 78 *Cell culture*

79 The 9L gliosarcoma cells were grown and maintained during their exponential growth phase  
80 in T75 cm<sup>2</sup> BD Falcon™ tissue culture flasks (Franklin Lakes, NJ, USA) containing Dulbecco's  
81 Modified Eagle Medium (DMEM) with L-Glutamine, supplemented with 10% (v/v) Fetal Bovine  
82 Serum (FBS) and 1% (v/v) Penicillin/Streptomycin (PenStrep). Cell cultures were passaged  
83 upon reaching 85% confluence to a concentration of 2–4 × 10<sup>4</sup> cells/cm<sup>2</sup> and stored at 37°C in  
84 a 5% (v/v) CO<sub>2</sub> cell culture incubator. In our hands, the cell doubling time was deduced to  
85 be 36 h. All chemical reagents used were purchased from GIBCO®, unless indicated otherwise.  
86 All cell culture work was carried out at the Illawarra Health and Medical Research Institute  
87 (Wollongong, NSW, Australia).

### 88 *Nanoparticle synthesis and preparation*

89 The cerium oxide nanoparticle sample was synthesised at the Institute for Superconducting  
90 and Electronic Materials (Wollongong, NSW, Australia) using a spray pyrolysis technique<sup>19,20</sup>.  
91 This synthesis approach produces compounds of high purity and chemical homogeneity, yielding  
92 a nanoparticle with reproducible size and characteristics. A 1 L aqueous solution was prepared,  
93 consisting of 0.45 mol/L of Ce(NO<sub>3</sub>)<sub>3</sub> and 6H<sub>2</sub>O. This solution was sprayed and decomposed at  
94 500°C using a customised spray pyrolysis system designed for the engineering of nanoceramics  
95 and composites. Cerium oxide NP samples were dried prior to sterilisation using an open furnace  
96 operating at 140°C for a period no less than 2 h. Sterilisation was achieved using an autoclave  
97 operating at 121°C on a dry cycle, with sterilised samples kept in glass vials surrounded by silica  
98 gel to avoid moisture absorption. Cerium oxide NPs were dispersed in Dulbecco's Phosphate-  
99 Buffered Saline (DPBS) to solubilise the NP. Sonication and vortex mixing was used to minimise

100 the size of NP aggregates and increase the homogeneity of dispersion prior to exposure. A  
101 concentration of 50  $\mu\text{g}/\text{ml}$  was applied to 9L cells for subsequent analysis.

### 102 *X-ray Diffraction*

103 A slurry of nanoparticle was produced via vigorous mixing with 100 % ethanol which was  
104 placed onto a quartz sample holder. The sample was presented to the monochromatic, copper  $K\alpha$   
105 X-ray beam ( $\lambda = 1.5406 \text{ \AA}$ ). The X-ray diffraction analysis was performed using an automated  
106 GBC® eMMA X-ray Diffractometer (GBC, VIC, Australia) where the sample was scanned using  
107 a step size of  $0.2^\circ 2\theta$  through the range of  $20^\circ - 70^\circ 2\theta$  with a count time of 8.75 seconds per  
108 step. The operational settings used were 25 mA and 40 kVp. Phase identification was extracted  
109 by comparing the recorded diffraction pattern with the Inorganic Crystal Structure Database  
110 (ICSD). The average nanoparticle crystallite size ( $\overline{Tc}$ ) is extracted from the X-ray diffraction  
111 data using Scherrer's equation (1).

$$\overline{Tc} = \frac{K\lambda}{\beta \cos(\theta_B)} \quad (1)$$

112 K is the shape factor constant ( $K = 0.89$ ),  $\lambda$  is the X-ray beam wavelength,  $\beta$  is the FWHM  
113 (in radians) and  $\theta_B$  is the Bragg angle.

### 114 *Transmission Electron Microscopy*

115 Transmission electron microscopy (TEM) was performed using a JEOL 2011 high resolution  
116 (HR) instrument, characterising the size and morphology of the sample. The samples were  
117 prepared by dispersion of  $\text{CeO}_2$  powders onto holey carbon support films.

### 118 *Gas sorption analysis*

119 The specific surface area of the powder samples was measured by the Brunauer-Emmett-  
120 Teller (BET) method with a Nova 1000 high speed gas sorption analyser from Quantachrome,  
121 using the adsorption of  $\text{N}_2$  at the temperature of liquid nitrogen. Prior to measuring, the samples  
122 were degassed at  $120^\circ\text{C}$  for 2 h 30 min in vacuum.

123 *Irradiation of cell culture*

124 All irradiations were performed in the radiation oncology department at the Prince of Wales  
125 Hospital (Randwick, NSW, Australia). The confluent cell culture was irradiated following a  
126 24 h incubation period with cerium oxide nanoparticles at a concentration of 50  $\mu\text{g}/\text{ml}$ . Prior  
127 to megavoltage irradiation, non-vented T12.5  $\text{cm}^2$  tissue culture flasks (BD Falcon<sup>TM</sup>) were  
128 completely filled with Hank's Balanced Salt Solution (HBSS) to ensure no air bubbles were  
129 present inside the flask, maximising the accuracy of the dose delivered at the depth of the cells.  
130 Kilovoltage irradiation was performed using only a 6 mm depth of medium in an attempt to  
131 maximise the accuracy of the dose delivered to the cell monolayer. Beam energies of 10 MV  
132 and 150 kVp were explored using an Elekta Axesse<sup>TM</sup> LINAC (Elekta AB, Kungstengsgatan,  
133 Stockholm, Sweden) and a Nucletron Oldelft Therapax DXT 300 Series 3 Orthovoltage unit  
134 (Nucletron B.V., Veenendaal, The Netherlands), respectively. All doses (1, 2, 3, 5 & 8 Gy)  
135 were delivered in single fractions at room temperature. Tissue culture flasks were irradiated in  
136 a horizontal orientation with solid water placed both underneath and around the sides of the  
137 flasks, primarily to maintain adequate backscattering effects and stabilise electronic equilibrium.  
138 Unirradiated control samples (with and without  $\text{CeO}_2$  NPs) were utilised and handled under the  
139 same conditions as the irradiated samples.

140 *Clonogenic cell survival assay*

141 Cell survival was assessed using a clonogenic cell survival assay, otherwise known as a colony-  
142 forming assay<sup>21,22</sup>. Adherent cell lines, such as 9L, have the ability to form colonies *in vitro* even  
143 at low density cell seeding. Following radiation exposure, all of the flasks were promptly plated,  
144 initiating the clonogenic assay (duration of 15 doubling times for 9L cells). The growth media was  
145 removed and the confluent cell culture was thoroughly washed with DPBS containing no calcium  
146 (Ca) or magnesium (Mg) salts. The cells were then detached from the surface of the flask with a 2-  
147 3 minute incubation with 0.05% trypsin ethylenediaminetetraacetic acid (Trypsin-EDTA), forming  
148 a cell suspension that was counted using a haemocytometer. Cells were seeded at low densities in  
149 triplicate into 100 mm Sigma-Aldrich® petri dishes containing 10 ml of the DMEM. All plates  
150 were incubated at 37°C and 5%  $\text{CO}_2$  for 15 cell doubling times. Each prescribed dose used a  
151 maximum of three different cell seeding numbers, all determined by preliminary experiments to

152 narrow the optimal seeding to achieve an approximate number of colonies of 100. Following the  
153 incubation period, formed colonies were fixed and stained using a solution comprised of 75%  
154 (v/v) ethanol and 25% (v/v) crystal violet (Sigma-Aldrich®). Colonies containing 50 cells or  
155 more, confirmed by the use of a high powered inverted microscope are counted for analysis.  
156 Cell survival data is presented using the relative surviving fraction of cells as a function of  
157 absorbed dose. The surviving fraction is extracted from the plating efficiency. The Plating  
158 Efficiency (PE) is calculated as the ratio of viable colonies to cells seeded.

$$PE = \frac{\text{No. of colonies counted}}{\text{No. of cells seeded}} \quad (2)$$

159 The Surviving Fraction (SF) was determined by comparing the PE at a given dose to the  
160 control (i.e. no dose). The surviving fraction is given by:

$$SF(D) = \frac{PE(D)}{PE(0)} \quad (3)$$

161 where SF(D) and PE(D) is the surviving fraction and plating efficiency at dose D (Gy),  
162 respectively.

163 PE(0) is the plating efficiency of unirradiated controls (0 Gy) with or without NPs used for  
164 normalisation of irradiated samples with or without NPs, respectively. The plating efficiencies  
165 given are the mean PE values from duplicate samples at each dose.

166

### 167 *Statistical analysis*

168 Cell survival experiments were replicated once and measured in triplicate on each occasion.  
169 The reported values are the mean of all experiments, with the experimental uncertainty given  
170 as one standard deviation. The LQ model was fitted to cell survival data using KaleidaGraph  
171 software. The fit of the data is weighted by the reported error at each dose in the determination of  
172 the radiobiological constants of the LQ model. Statistical analysis of toxicity data was performed  
173 using a two-tailed Student's *t*-test using the assumption of equal variance. A *P* value of  $\leq 0.05$   
174 was considered statistically significant.

176 The cell survival curves are constructed on a semi-logarithmic plot of the surviving fraction  
 177 as a function of absorbed dose. The cell survival curve can be represented mathematically using  
 178 the linear quadratic (LQ) model as X-ray (i.e. low LET) radiation sources are used<sup>2,23</sup>.

$$SF(D) = \exp(-\alpha D - \beta D^2) \quad (4)$$

179 The parameters  $\alpha$  ( $\text{Gy}^{-1}$ ) and  $\beta$  ( $\text{Gy}^{-2}$ ) are measures of the radiosensitivity and repair  
 180 accumulation, respectively. The surviving fraction data was fitted to the LQ model using  
 181 KaleidaGraph software, extracting the  $\alpha$  and  $\beta$  constants for each set of cell survival data.

### 182 *Protection enhancement ratio*

183 The Protection Enhancement Ratio (PER) is a value used to measure the degree of protection  
 184 achieved using  $\text{CeO}_2$  NPs. The PER can be defined as the ratio of doses in the presence of  $\text{CeO}_2$   
 185 to the control (i.e. no NP), as measured at the common endpoint of 10 % cell survival.

$$PER_{SF=10\%} = \frac{Dose_{\text{CeO}_2}}{Dose_{\text{control}}} \quad (5)$$

186 A PER value greater than 1 is indicative of radioprotection, whereas a PER value less than 1  
 187 reveals a sensitisation effect. This effect is manifested as a direct result of the presence of  $\text{CeO}_2$   
 188 NPs.

## 189 **Results**

### 190 *Phase and structural characterisation of cerium oxide*

191 The biochemical effect of nanoparticles are dependent on their structural and physical char-  
 192 acteristics. Characteristics of particular interest include: phase composition, structure and  
 193 crystallite size. First order diffraction peaks have been labelled (Figure 1, **A**) upon correlating  
 194 recorded data against the ICSD (PDF card no. 01-089-8436). Cerium oxide nanoparticle's phase  
 195 is confirmed to exist as  $\text{CeO}_2$ . This matches the phase of the cerium oxide NPs that have been  
 196 reported to provide protection in response to exposure of ionising radiation<sup>3,5-7</sup>. Using the XRD

197 data, the structure of the sample can be extracted. The CeO<sub>2</sub> NP sample has a simple cubic  
198 crystalline structure with a single lattice parameter,  $a = 5.4112 \text{ \AA}$ . The average crystallite size  
199 can be extracted from the XRD peaks using Scherrer's equation. The most accurate analysis  
200 is achieved by selecting the most pronounced peaks, free of any contribution from surrounding  
201 satellite peaks. The average crystallite size was calculated to lie in the range of 6–8 nm, consistent  
202 with the crystallite sizes observed in the HR-TEM image (Figure 1, **B**). The high resolution  
203 transmission electron micrograph (HR-TEM) shows clear lattice fringes (Figure 1, **B**) with a  
204 fringe spacing ( $d$ ) of  $3.15 \text{ \AA}$ , which corresponds to the distance between the 111 lattice planes of  
205 CeO<sub>2</sub>. The calculated BET specific surface area of the nanocrystalline powder was  $51 \text{ m}^2/\text{g}$ .

#### 206 *Toxicity of CeO<sub>2</sub> NPs to 9L cells*

207 No definitive conclusions have been made regarding the toxicity of CeO<sub>2</sub> NPs<sup>3,6,7,24</sup>. Efforts  
208 to determine its biological viability remains the subject of numerous studies and is an integral  
209 component to the development of any model using CeO<sub>2</sub><sup>8,10,11,24–27</sup>. Initially, we investigated the  
210 toxicity of our synthesised CeO<sub>2</sub> NP to 9L cells. **The clonogenic cell survival assay was conducted**  
211 **following a 24 h incubation with CeO<sub>2</sub> NPs at a range of concentrations up to 500  $\mu\text{g}/\text{ml}$ . We**  
212 **established that the application of CeO<sub>2</sub> NPs had no statistically significant toxic effect on the**  
213 **surviving fraction of 9L cells at 50  $\mu\text{g}/\text{ml}$  (Figure 2) where we found a surviving fraction of**  
214  **$0.93 \pm 0.07$  ( $P$  value: 0.2, CeO<sub>2</sub> vs no NP control). The toxicity of CeO<sub>2</sub> NPs is found to**  
215 **be concentration dependent and this effect should be considered when implementing CeO<sub>2</sub> as a**  
216 **radioprotector.**

#### 217 *Efficacy of CeO<sub>2</sub> NPs when used in synergy with different X-ray beams*

218 The gliosarcoma cell line, 9L, was exposed to CeO<sub>2</sub> NPs at a concentration of  $50 \mu\text{g}/\text{ml}$  during  
219 a 24 h incubation period prior to irradiation. The control flasks were incubated in the absence  
220 of the NP. All conditions remained constant besides the presence and absence of the NP. The  
221 first X-ray beam used was a 150 kVp beam and was **chosen for both, its clinical relevance and to**  
222 **maximise the dose enhancement to the CeO<sub>2</sub> doped medium to a water equivalent medium based**  
223 **on the formalism described by Corde et al.<sup>28</sup> The 150 kVp beam produces an effective energy**  
224 **of 65 keV which lies close to, yet above the energy required to maximise dose enhancement (i.e.**

225 54 keV). The cells were exposed to a range of doses up to 8 Gy. The samples were irradiated  
226 using either a 150 kVp or 10 MV X-ray beam to probe the effectiveness of CeO<sub>2</sub> NPs across a  
227 range of beam energies. Cell survival curves were produced using the clonogenic cell survival  
228 assay. This technique enabled any effect caused by the presence of the NP to be observed and  
229 quantified. The results show that the 9L cell line has a response that varies with treatment  
230 beam energy (Figure 3). The radiobiological parameters ( $\alpha$ ,  $\beta$ ) for 9L cells are investigated for  
231 different radiation sources in the presence and absence of CeO<sub>2</sub> NPs. It is evident that CeO<sub>2</sub>  
232 NPs exhibit a protective effect to 9L cells when irradiated using a 10 MV photon beam (Figure  
233 3, **A**). A higher surviving fraction at all doses was observed in the presence of CeO<sub>2</sub> NPs relative  
234 to the control sample. The radiosensitivity of 9L cells decreases in the presence of CeO<sub>2</sub> NPs  
235 with a corresponding increase in the damage repair as portrayed throughout table 1. A PER  
236 value of  $1.23 \pm 0.003$  is achieved during the 10 MV treatment, confirming the radioprotective  
237 ability of CeO<sub>2</sub> NPs. A contrary effect is observed in response to exposure from the 150 kVp  
238 X-ray beam (Figure 3, **B**), where the surviving fraction in the presence of CeO<sub>2</sub> NPs is similar  
239 to the 9L control sample, revealing the consequence of the high-Z component of CeO<sub>2</sub> NPs. We  
240 observe a minor increase in radiosensitivity of 9L cells in the presence of CeO<sub>2</sub> coupled with  
241 the lack of evidence of damage repair, which is confirmed from the linear trend of the survival  
242 curve (Table 1). Subsequently, a PER close to unity is deduced, suggesting that CeO<sub>2</sub> NPs  
243 possess an energy-dependent radioprotection efficacy. We believe that a counterbalance between  
244 the sensitisation effect caused by increases in the RBE at lower photon energies<sup>15,29</sup> and the  
245 radioprotection offered through CeO<sub>2</sub>'s free-radical scavenging ability<sup>6</sup> is responsible for these  
246 energy-dependent effects.

## 247 Discussion

248 The application of CeO<sub>2</sub> NPs to clinical radiation protection is the subject of numerous  
249 studies and development<sup>3,5-7</sup>. Nanomedicine is a vastly expanding and alternative approach to  
250 existing medicines with applications ranging from diagnostic imaging and therapeutic radiation  
251 enhancement to radiation protection<sup>6,15,30</sup>. Minimising radiation-induced side effects is the focus  
252 of many studies and the catalyst in the production and development of novel approaches to  
253 radiation protection<sup>28,31</sup>. Scavenging free radicals is the most common approach used to provide

254 radiation protection. Development of new and improved radioprotectors as an alternative to  
255 amifostine is of great importance as a result of its clinical limitations<sup>3,9</sup>.

256 We synthesised CeO<sub>2</sub> NPs using spray pyrolysis techniques for their application in radiation  
257 protection. High nanoparticle yield and reproducible characteristics such as size, phase and  
258 crystallinity are key advantages provided by our synthesising approach over alternative techniques  
259 of nanoparticle production<sup>32</sup>. Characterisation of our synthesised sample using XRD revealed  
260 important properties that were essential for our application. Results show that we have a  
261 nanoparticle sample with a single cubic phase, existing as CeO<sub>2</sub> upon comparison with the  
262 ICSD. The broad diffraction peaks (Figure 1) confirm the nano-crystallinity of CeO<sub>2</sub>, with  
263 the mean crystallite size measured to range from 6–8 nm. Tarnuzzer et al.<sup>7</sup> report parallel  
264 findings with their XRD analysis of CeO<sub>2</sub>, enabling us to suggest that our synthesised sample  
265 also exhibits these autoregenerative antioxidant effects for radiation protection. The HR-TEM  
266 image of CeO<sub>2</sub> shows crystallite sizes that correlate with that determined in our X-ray diffraction  
267 analysis. Distinct lattice fringes are observed, supporting the presence of a cubic structure with  
268 the distance between successive fringes deduced to be 3.15 Å, consistent with our diffraction data  
269 and the PDF card no. 01-089-8436 as published in the ICS database. [Light micrographs of 9L  
270 cells incubated with CeO<sub>2</sub> NPs show that they are randomly distributed, i.e. around, on and  
271 alternately in the cells. However at such magnification, it is not possible to visualise intracellular  
272 localisation. Using flow cytometric analysis we deduce that CeO<sub>2</sub> NPs can be internalised in 9L  
273 cells. The internalisation is confirmed as a result of increases in the measured cell side scatter  
274 \(data not shown\), a technique utilised by Busch et al.<sup>33</sup> Results of the gas sorption analysis show  
275 a nanocrystalline surface area of 51 m<sup>2</sup>/g, supporting the nanoscale crystallite size recorded. It  
276 is well known that the size of a nanoparticle is related its surface area, where smaller particles  
277 have greater surface areas<sup>11</sup>. Increasing the surface area could therefore act to maximise any  
278 related free-radical scavenging properties of CeO<sub>2</sub> NPs.](#)

279 The toxicity of CeO<sub>2</sub> NPs to 9L cells was tested to elucidate its clonogenic survival **at concen-**  
280 **trations up to 500 µg/ml**. We utilised mimetic experimental conditions to that used in radiation  
281 exposures, maximising the validity of the reported outcomes. Following a 24 h incubation of  
282 9L cells with CeO<sub>2</sub> NPs, we report insignificant toxic effects **at 50 µg/ml**, consistent with other  
283 published literature<sup>6,7,27</sup>. Inconsistent conclusions have been made in regard to the toxic effects

284 of CeO<sub>2</sub> NPs, a factor requiring further development<sup>26</sup>. It is well documented that the size  
285 and structure of nanoparticles, influenced by the production process, dictate their toxicity<sup>6,26</sup>.  
286 Additional factors which should be investigated include: oxygen non-stoichiometry and balance  
287 of Ce<sup>3+</sup>/Ce<sup>4+</sup> cation states, exposure time, concentration and aggregation of the nanoparticle,  
288 and also cell type as different toxic responses may occur<sup>10</sup>.

289 It has been well established that CeO<sub>2</sub> NPs utilise a unique free-radical scavenging ability to  
290 provide radioprotection in both cell culture and murine models. Important factors influencing  
291 the effectiveness of CeO<sub>2</sub> include: cell sensitivity, NP concentration and synthesis and these  
292 factors should be further developed and understood in steps toward clinical acceptance.

293 Figure 3A clearly indicates that the CeO<sub>2</sub> NPs provide protection against radiation induced  
294 damage to gliosarcoma (9L) cells. Cell survival curves provide a wealth of information — not  
295 only a comparison of the response of cells exposed to radiation in the presence and absence  
296 of CeO<sub>2</sub>, but the influence of CeO<sub>2</sub> on the radiobiological parameters,  $\alpha$  and  $\beta$  used in the LQ  
297 model. Using a 10 MV photon beam, we record radioprotection at all doses up to 8 Gy with CeO<sub>2</sub>  
298 NPs at a concentration of 50  $\mu\text{g}/\text{ml}$ . This radioprotection is supported by the increase in damage  
299 repair ( $\beta$ ) and decrease in radiosensitivity ( $\alpha$ ) under the LQ model data interpretation observed  
300 in the presence of CeO<sub>2</sub> NPs. While statistically there is no significant difference between the  
301 two survival curves at 150 kVp, analysis of the data under the LQ model indicates an increased  
302 linearity of the survival curve in the presence of the NP. Investigation of the radiobiological  
303 parameters within the LQ model shows a small increase in the radiosensitivity when CeO<sub>2</sub> NPs  
304 are present. Within the LQ model the increased linearisation is interpreted as a change in the  
305 radiation spectrum. Therefore the increased linearity of the logarithmic cell survival suggests  
306 that CeO<sub>2</sub> NPs enable more direct damage effects to occur due to the additional enhancement  
307 in the field of low energy electrons.

308 The observed energy dependence of the PER efficacy (for 10 MV and 150 kVp) can be explained  
309 as a counterbalance between the free-radical scavenging ability of CeO<sub>2</sub> and the increased RBE  
310 due to lower energy radiations. The increase in the RBE is, in part, influenced by the macroscopic  
311 dose enhancement from the mass-energy absorption of CeO<sub>2</sub> and the increased yield of Auger  
312 electrons<sup>29,34,35</sup>. This energy dependence is also influenced by the increased production of photo-  
313 electrons, with a cross-section that is inversely proportional with energy (Figure 4). Photoelectric

314 interactions are important to consider for compounds such as  $\text{CeO}_2$  as the effective atomic  
315 number ( $Z_{eff}=54$ )<sup>36</sup> has a strong influence on the photoelectric cross-section<sup>13</sup>. **Photoelectric**  
316 **interactions stimulate two main processes – the ejection of characteristic X-rays and Auger**  
317 **electron cascades**<sup>37,38</sup>. Auger electrons increase the average LET of the resultant secondary  
318 particles maximising the efficiency of these radiations through denser ionisations, imparting  
319 more direct damage which in turn reduces the abundance of reactive oxygen species responsible  
320 for indirect damage<sup>17</sup>. The 150 kVp X-rays yield a greater proportion of these higher LET  
321 particles than the 10 MV photon beam in the presence of  $\text{CeO}_2$  NPs, supporting the energy  
322 dependent efficacy of radioprotection that we observe. Ideally, a radioprotective compound  
323 would have a low atomic number to minimise effects such as energy dependent protection. The  
324 use of low-Z radioprotectors is supported by the current “gold standard” clinical radioprotector,  
325 amifostine, which has a low effective atomic number ( $Z_{eff}=11$ ). As radioprotectors generally  
326 function along a chemical pathway, the cross-section for the production of secondary particles  
327 should be minimised. The effect of the atomic number on the total photon interaction cross-  
328 section supports the notion that idealistic radioprotectors should have a low atomic number in  
329 order to be less dependent of the X-ray field energy spectra (Figure 4, **B**).

330 In conclusion we have demonstrated that the radioprotection (via free-radical scavenging) efficacy  
331 of the  $\text{CeO}_2$  nanoparticle depends on the spectra of X-ray radiation. Our hypothesis is that  
332 the change in efficacy is driven by the high-Z component of  $\text{CeO}_2$  that leads to a modifica-  
333 tion of the electron spectra in close proximity to the nanoparticles that can counterbalance  
334 the radioprotection efficacy of  $\text{CeO}_2$ . The electron spectra is modified through the increased  
335 production of low energy secondary electrons (including Auger cascades) that are generated  
336 due to predominance of the photoelectric effect at kilovoltage X-ray energies. The influence  
337 of these low energy electrons, with high LET, is reflected in the change of the shape of the  
338 survival curve for 9L cells exposed to  $\text{CeO}_2$  nanoparticles and irradiated with 150 kVp X-rays  
339 compared to 10 MV X-rays, which adds weight to our hypothesis. Therefore we have highlighted  
340 a very interesting phenomenon that must be considered if radiation protection drugs for use in  
341 radiotherapy are developed based on the  $\text{CeO}_2$  nanoparticle. This is particularly important in the  
342 case of cancer treatment delivered by different photon fields (e.g. superficial cancer treatment  
343 with 100 - 150 kVp photons in comparison with external beam radiotherapy delivered by 6-

344 18 MV photons) where we have shown that the changes in the free-radical scavenging efficacy of  
345 CeO<sub>2</sub> nanoparticles are pronounced. The scientific interest in the development of CeO<sub>2</sub> NPs as a  
346 radioprotecting agent is evident throughout the widespread literature that contains both, *in-vitro*  
347 and *in-vivo* models<sup>3,5-8,10,24-27</sup>. Expanding our knowledge in the application and functionality  
348 of CeO<sub>2</sub> NPs will continue with the long term goal of clinical implementation.

## 349 Acknowledgments

350 We gratefully acknowledge the Illawarra Health & Medical Research Institute for the use of  
351 the facility.

## 352 References

- 353 [1] Allard, E., Jarnet, D., Vessieres, A., Vinchon-Petit, S., Jaouen, G., Benoit, J., et al.  
354 Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a  
355 synergistic treatment against intracranial 9L glioma xenograft. *Pharm Res* 2010;27:56–64.
- 356 [2] Metcalfe, P., Kron, T., Hoban, P.. *The Physics of Radiotherapy, X-rays and Electrons*.  
357 Madison, Wisconsin: Medical Physics Publishing; 2007.
- 358 [3] Madero-Visbal, R.A., Alvarado, B.E., Colon, J.F., Baker, C.H., Wason, M.S., Das,  
359 S., et al. Harnessing nanoparticles to improve toxicity after head and neck radiation.  
360 *Nanomedicine* 2012;xx:1–9. Doi:10.1016/j.nano.2011.12.011.
- 361 [4] Castedo, M., Perfettini, J., Roumier, T., Andreau, K., Medema, R., Kroemer, G.. Cell  
362 death by mitotic catastrophe: a molecular definition. *Oncogene* 2004;23:2825–2837.
- 363 [5] Rzigalinski, B.A., Bailey, D., Chow, W., Kuiry, S.C., Patil, S., Merchant, S.. Cerium  
364 oxide nanoparticles increase the lifespan of cultured brain cells and protect against free  
365 radical and mechanical trauma. *FASEB J* 2003;17:606–606.
- 366 [6] Colon, J., Herrera, L., Smith, J., Patil, S., Komanski, C., Kupelian, P., et al. Protection  
367 from radiation-induced pneumonitis using cerium oxide nanoparticles. *Nanomedicine*  
368 2009;5:225–231.

- 369 [7] Tarnuzzer, R.W., Colon, J., Patil, S., Seal, S.. Vacancy engineered ceria nanostructures  
370 for protection from radiation-induced cellular damage. *Nano Lett* 2005;5:2573–2577.
- 371 [8] Rzigalinski, B.A., Meehan, K., Davis, R.M., Xu, Y., Miles, W.C., Cohen, C.A.. Radical  
372 nanomedicine. *Nanomedicine* 2006;1:399–412.
- 373 [9] Grdina, D., Murley, J., Kataoka, Y.. Radioprotectants: Current status and new directions.  
374 *Oncology* 2002;63:2–10.
- 375 [10] Lin, W., Huang, Y., Zhou, X., Ma, Y.. Toxicity of cerium oxide nanoparticles in human  
376 lung cancer cells. *Int J Toxicol* 2006;25:451–456.
- 377 [11] Sager, T.M., Porter, D.W., Robinson, V.A., Lindsley, W.G., Schwegler-Berry, D.E.,  
378 Castranova, V.. Improved method to disperse nanoparticles for in vitro and in vivo  
379 investigation of toxicity. *Nanotoxicology* 2007;1:118–129.
- 380 [12] Buzea, C., Pacheco, I.I., Robbie, K.. Nanomaterials and nanoparticles: sources and  
381 toxicity. *BioInterphases* 2007;2:17–71.
- 382 [13] Attix, F.. *Introduction to Radiological Physics and Radiation Dosimetry*. Weinheim,  
383 Germany: Wiley-VCH; 2004.
- 384 [14] Rahman, W.N., Bishara, N., Ackerly, T., He, C.F., Jackson, P., Wong, C., et al.  
385 Enhancement of radiation effects by gold nanoparticles for superficial radiation therapy.  
386 *nanomedicine* 2009;5:136–142.
- 387 [15] Butterworth, K.T., Coulter, J.A., Jain, S., Forker, J., McMahon, S.J., Schettino, G.,  
388 et al. Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles:  
389 potential application for cancer therapy. *Nanotechnology* 2010;21:295101–295709.
- 390 [16] Kahn, F.M.. *The Physics of Radiation Therapy*. Maryland, USA: Williams and Wilkins;  
391 1994.
- 392 [17] Tubiana, M., Dutreix, J., Wambersie, A.. *Introduction to Radiobiology*. United Kingdom:  
393 Taylor & Francis; 1990.

- 394 [18] Sastry, K.S.R.. Biological effects of the Auger emitter iodine-125 A review. Report No. 1  
395 of AAPM Nuclear Medicine Task Group No. 6. *Medical Physics* 1992;19:1361–1370.
- 396 [19] Konstantinov, K., Stambolova, I., Peshev, P., Darriet, B., Vassilev, S.. Preparation of  
397 ceria films by spray pyrolysis method. *Int J Inorg Mater* 2000;2:277–280.
- 398 [20] Truffault, L., Winton, B., Choquet, B., Andrezza, C., Simmonard, C., Devers, T.,  
399 et al. Cerium oxide based particles as possible alternative to ZnO in sunscreens: Effect of  
400 the synthesis method on the photoprotection results. *Mater Lett* 2012;68:357–360.
- 401 [21] Langdon, S.. *Cancer Cell Culture: methods and protocols*. Totowa, New Jersey: Humana  
402 Press; 2004.
- 403 [22] Puck, T.T., Marcus, P.I.. Action of x-rays on mammalian cells. *J Exp Med* 1956;103:653–  
404 666.
- 405 [23] Brenner, D.. The Linear-Quadratic model is an appropriate methodology for determining  
406 isoeffective doses at large doses per fraction. *Semin Radiat Oncol* 2008;18:234–239.
- 407 [24] Thill, A., Zeyons, O., Spalla, O., Chauvat, F., Rose, J., Auffan, M., et al. Cytotoxicity  
408 of CeO<sub>2</sub> nanoparticles for escherichia coli. physico-chemical insight of the cytotoxicity  
409 mechanism. *Environmental Science and Technology* 2006;40:6151–6156.
- 410 [25] Nalabotu, S.K., Kolli, M.B., Triest, W.E., Ma, J.Y., Manne, N.D., Katta, A., et al.  
411 Intratracheal instillation of cerium oxide nanoparticles induces hepatic toxicity in male  
412 Sprague-Dawley rats. *Int J Nanomed* 2011;6:2327–2335.
- 413 [26] Park, E., Choi, J., Park, Y.. Oxidative stress induced by cerium oxide nanoparticles in  
414 cultured BEAS-2B cells. *Toxicology* 2008;245:90–100.
- 415 [27] Xia, T., Kovoichich, M., Liang, M., Madler, L., Gilbert, B., Shi, H., et al. Comparison of  
416 the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution  
417 and oxidative stress properties. *ACS Nano* 2008;2:2121–2134.
- 418 [28] Corde, S., Joubert, A., Adam, J.F., Charvet, A.M., Le Bas, J.F., Esteve, F.,  
419 et al. Synchrotron radiation-based experimental determination of the optimal energy for

- 420 cell radiotoxicity enhancement following photoelectric effect on stable iodinated compounds.  
421 *British Journal of Cancer* 2004;91:544–551.
- 422 [29] McMahon, S.J., Hyland, W.B., Muir, M.F., Coulter, J.A., Jain, S., Butterworth, K.T.,  
423 et al. Biological consequences of nanoscale energy deposition near irradiated heavy atom  
424 nanoparticles. *Sci Rep* 2011;1:1–9.
- 425 [30] Moghimi, S.M., Hunter, A.C., Murray, J.. Nanomedicine: current status and future  
426 prospects. *FASEB J* 2005;19:311–330.
- 427 [31] Hendry, J.H., Jeremic, B., Zubizarreta, E.. Normal tissue complications after radiation  
428 therapy. *Pan Am J Public Health* 2006;20:151–160.
- 429 [32] Madler, L., Kammler, H.K., Mueller, R., Pratsinis, S.. Controlled synthesis of  
430 nanostructured particles by flame spray pyrolysis. *J Aerosol Sci* 2002;33:369–389.
- 431 [33] Busch, W., Bastian, S., Trahorsch, U., Iwe, M., Kuhnel, D., Meibner, T., et al.  
432 Internalisation of engineered nanoparticles into mammalian cells in-vitro: influence of cell  
433 type and particle properties. *J Nanopart Res* 2011;13:293–310.
- 434 [34] Robar, J.L., Riccio, S.A., Martin, M.A.. Tumour dose enhancement using modified  
435 megavoltage photon beams and contrast media. *Phys Med Bio* 2002;47:2433–2449.
- 436 [35] McMahon, S.J., Mendenhall, M.H., Jain, S., Currell, F.. Radiotherapy in the presence  
437 of contrast agents: a general figure of merit and its application to gold nanoparticles. *Phys*  
438 *Med Bio* 2008;53:5635–5651.
- 439 [36] Boone, J.M., Chavez, A.. Comparison of X-ray cross sections for diagnostic and therapeutic  
440 medical physics. *J Med Phys* 1996;23:1997–2005.
- 441 [37] Kobayashi, K., Usami, N., Porcel, E., Lacombe, S., Le Sech, C.. Enhancement of  
442 radiation effect by heavy elements. *Mutat Res* 2010;704:123–131.
- 443 [38] Porcel, E., Liehn, S., Remita, H., Usami, N., Kobayashi, K., Furusawa, Y., et al.  
444 Platinum nanoparticles: a promising material for future cancer therapy? *Nanotechnology*  
445 2010;21:1–7.

Figure 1: X-ray diffraction spectrum of the CeO<sub>2</sub> NP sample synthesised by spray pyrolysis (**A**). Data was acquired using an automated GBC® eMMA X-ray Diffractometer. X-ray diffraction peaks were assigned Miller indices in correlation with the ICSD. High Resolution Transmission Electron Microscopy image of CeO<sub>2</sub> NPs synthesised using spray pyrolysis techniques (**B**).

Figure 2: The surviving fraction of 9L cells exposed to CeO<sub>2</sub> NPs during a 24 h exposure at increasing concentrations up to 500 µg/ml. The toxicity was measured using the clonogenic cell survival assay. Surviving fraction data is presented with uncertainties given as one standard deviation with statistical significance measured with a  $P$  value  $\leq 0.05$ .



Figure 3: 9L clonogenic cell survival after irradiation with 10 MV (**A**) or 150 kVp (**B**) X-ray beams in the presence (triangle) and absence (square) of CeO<sub>2</sub> NPs at a concentration of 50 µg/ml. All uncertainties are presented with one standard deviation made from duplicate samples which are measured in triplicate.


Figure 4: Energy dependence of the mass-energy absorption coefficients for the three main radiation interactions are highlighted as a function of treatment beam energy for CeO<sub>2</sub> (**A**). The total mass-energy absorption coefficients for amifostine and CeO<sub>2</sub> are shown over a range of energies (**B**) highlighting the influence on the mass-energy absorption coefficient through increases in atomic number.



Table 1: Summary of the radiobiological parameters for 9L cells exposed to different radiation sources in the presence and absence of CeO<sub>2</sub> NPs. The LQ model was used to fit the surviving fraction data in KaleidaGraph, extracting the  $\alpha$  and  $\beta$  constants. All uncertainties listed are given as one standard deviation.



**Table 1**[Click here to download Table: Table 1.docx](#)

Experimental Parameters				
Radiation source	Control		50 µg/ml	
	$\alpha$ (Gy <sup>-1</sup> )	$\beta$ (Gy <sup>-2</sup> )	$\alpha$ (Gy <sup>-1</sup> )	$\beta$ (Gy <sup>-2</sup> )
150 kVp X-rays	0.21 ± 0.03	0.009 ± 0.004	0.30 ± 0.04	--
10 MV X-rays	0.20 ± 0.06	0.013 ± 0.008	0.06 ± 0.04	0.019 ± 0.005







**A****B**